


PRODUCT INFORMATION



DuP-697

Item No. 70645

CAS Registry No.: 88149-94-4
Formal Name: 5-bromo-2-(4-fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-thiophene
MF: C₁₇H₁₂BrFO₂S₂
FW: 411.3
Purity: ≥98%
UV/Vis.: λ_{max}: 254, 300 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

DuP-697 is supplied as a crystalline solid. A stock solution may be made by dissolving the DuP-697 in the solvent of choice, which should be purged with an inert gas. DuP-697 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of DuP-697 in these solvents is approximately 7, 15, and 54 mg/ml, respectively.

DuP-697 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, DuP-697 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. DuP-697 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

DuP-697 is a member of the diaryl heterocycle group of selective COX-2 inhibitors which includes MK-966 (rofecoxib), SC-58125, and celecoxib. DuP-697 is a potent and time-dependent inhibitor of COX-2.¹ When tested on isolated recombinant enzymes, DuP-697 is at least 50 times more potent in the inhibition of COX-2 than COX-1.² The IC₅₀ values for human recombinant COX-2 are 80 and 40 nM at 5 and 10 minutes, respectively.³ The IC₅₀ for the inhibition of human recombinant COX-1 after the same time intervals is 9 μM.³ DuP-697 also attenuates the COX-1 inhibitory activity of non-selective COX inhibitors such as indomethacin.⁴

References

1. Kargman, S., Wong, E., Greig, G.M., *et al.* Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells. *Biochem. Pharmacol.* **52**, 1113-1125 (1996).
2. Seibert, K., Masferrer, J., Needleman, P., *et al.* Pharmacological manipulation of cyclooxygenase-2 in the inflamed hydronephrotic kidney. *Br. J. Pharmacol.* **117**, 1016-1020 (1996).
3. Johnson, J.L. [Unpublished] (2000).
4. Rosenstock, M., Danon, A., and Rimon, G. PGHS-2 inhibitors, NS-398 and DuP-697, attenuate the inhibition of PGHS-1 by aspirin and indomethacin without altering its activity. *Biochim. Biophys. Acta* **1440**, 127-137 (1999).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/13/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM